Syapse Raises $10M in Series B Financing

syapseSyapse, a Palo Alto, CA-based developer of a Precision Medicine Data Platform, raised $10m in Series B financing.

The round was led by Safeguard Scientifics (NYSE:SFE) with participation from Series A investor The Social+Capital Partnership.

The company, which has raised a total of $14.5m, intends to use the funds to utilize genomics and clinical data to support treatment decisions as well as expand sales, marketing and client services, as well as further accelerate product development.

Led by Glenn Winokur, cofounder and CEO, Syapse enables academic and community healthcare providers to integrate complex genomic and clinical data with care pathways and medical knowledge bases to provide clinicians with actionable insights at point of care, enabling diagnosis, treatment, and outcomes tracking. The platform enables longitudinal tracking of patients over time, creating expansive sources of real world evidence that will be used to power learning health systems across networks of affiliated health providers. The platform integrates data from electronic medical records, molecular testing labs, imaging and billing systems, and is agnostic to the data source or system.

Today, Syapse software is being used to transform the care of complex diseases, such as cancer.



Join the discussion